| Assessment Status | Rapid Review Complete |
| HTA ID | - |
| Drug | Rifaximin |
| Brand | Targaxan® |
| Indication | Is indicated for the reduction in recurrence of episodes of overt hepatic encephalopathy in patients ≥ 18 years of age. |
| Assessment Process | |
| Rapid review commissioned | 09/07/2013 |
| Rapid review completed | 06/08/2013 |
| Rapid review outcome | Full Pharmacoeconomic Evaluation not Recommended |